Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Status:
Recruiting
Trial end date:
2024-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is
to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by
intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device
in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose
expansion stage.
Phase:
Phase 2
Details
Lead Sponsor:
Inovio Pharmaceuticals
Collaborators:
Coalition for Epidemic Preparedness Innovations Coalition for Epidemic Preparedness Innovations (CEPI)